Real-World Experience Using Bimekizumab in a Patient Cohort With Plaque-Type Psoriasis and Chronic Kidney Disease: A 48-Week Retrospective Multicentre Study.

References:

• C. C. Chi, J. Wang, Y. F. Chen, S. H. Wang, F. L. Chen, and T. H. Tung, “Risk of Incident Chronic Kidney Disease and End‐Stage Renal Disease in Patients With Psoriasis: A Nationwide Population‐Based Cohort Study,” Journal of Dermatological Science 78 (2015): 232–238, https://doi.org/10.1016/j.jdermsci.2015.03.012.
• C. B. Chen, Y. T. Huang, C. C. Hsiao, S. H. Chang, and C. C. Chi, “Real‐World Effects of Biologics on Renal Function in Psoriatic Patients: A Retrospective Study,” BioDrugs 36 (2022): 657–666, https://doi.org/10.1007/s40259‐022‐00547‐5.
• S. Sood, A. Rimke, B. D. Rankin, et al., “Real‐World Experience of Bimekizumab for Adult Patients With Plaque Psoriasis: A 52‐Week Multicenter Retrospective Study,” Journal of the American Academy of Dermatology 91 (2024): 936–939, https://doi.org/10.1016/j.jaad.2024.05.085.
• L. Gargiulo, A. Narcisi, L. Ibba, et al., “Effectiveness and Safety of Bimekizumab for the Treatment of Plaque Psoriasis: A Real‐Life Multicenter Study‐IL PSO (Italian Landscape Psoriasis),” Frontiers in Medicine 10 (2023): 1243843, https://doi.org/10.3389/fmed.2023.1243843.
• S. M. Laville, V. Gras‐Champel, A. Hamroun, et al., “Kidney Function Decline and Serious Adverse Drug Reactions in Patients With CKD,” American Journal of Kidney Diseases 83 (2024): 601–614.e1., https://doi.org/10.1053/j.ajkd.2023.09.012.